Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels.
Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis
Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis.
Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors.
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Architecture of human mTOR complex 1.
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)
Efficacy and safety study of RPC1063 in relapsing multiple sclerosis patients
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.
Thrombotic microangiopathy associated with interferon beta.
The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart.
More to come: humoral immune responses in MS.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Tcelna® (imilecleucel-T)
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.

Pages